期刊文献+

肺癌骨转移的诊断和临床特征分析 被引量:14

Diagnosis and clinical feature of lung cancer with bone metastasis
原文传递
导出
摘要 目的总结分析肺癌骨转移的临床特点并探讨其诊断方法。方法临床资料回顾性分析60例肺癌骨转移患者的临床特征和最佳检查方法。结果肺癌骨转移的早期阶段患者临床主要表现为不同程度的疼痛,亦可无临床症状。60例肺癌骨转移患者中腺癌35例(58.3%),鳞癌16例(26.7%),小细胞肺癌7例(11.7%),混合癌2例(3.3%)。骨转移部位有胸部70.0%,脊柱65.0%,骨盆53.3%,四肢45.0%,头颅38.3%。结论肺癌骨转移以多发性、溶骨性骨破坏为特征。腺癌骨转移发生率最高,其次为鳞癌及小细胞癌。通过放射性核素显像(ECT)、X线平片、电子计算机断层扫描(CT)、磁共振(MRI)能协助肺癌骨转移的诊断。 Objective To review clinical feature of lung cancer with bone metastasis and explore its diagnosed method. Methods The clinical materials were retrospectively analysed for clinical feature and best detection of 60 cases in lung cancer with bone metastasis. Results Patients of lung cancer with bone metastasis in early stage performed pain with different extent, or no clinical symptom either. In all the 60 cases, 58.3% were adenocarcinoma, 26.7% were squamous carcinoma, 11.7% were small cell lung cancer, 3.3% were mixed carcinoma. The frequencies of metastasis sites were as follows, eg, ribs(70.0% ), spine (65.0%) , pelvis(53.3% ), limbs(45.0% )and skull(38.3% ). Conclusions Bone metastasis in lung cancer is characterized by multiple osteolytic damages. Adenocarcinoma is one of the most common types of lung cancer that causes bone metastasis, while squamous carcinoma and small cell lung cancer are in the next place. ECT bone scan, X-ray, CT, and MRI are effective methods for early diagnosis of lung cancer with bone metastasis.
作者 贺学荣
出处 《中华肺部疾病杂志(电子版)》 CAS 2009年第1期14-15,共2页 Chinese Journal of Lung Diseases(Electronic Edition)
关键词 肺肿瘤 骨转移 诊断 放射性核素显像 Lung cancer Bone metastasis Diagnosis Emission computer tomograph
  • 相关文献

参考文献4

二级参考文献10

  • 1de la Piedra C, Castro-Errecaborde NA, Traba ML, et al.Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta, 2003;331(1-2):45.
  • 2Alexandrakis MG, Passam FH, Malliaraki N, et al. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta,2002;325(1-2):51.
  • 3Costa L, Demers LM, Gouveia-Oliveira A,et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol, 2002;20(3):850.
  • 4Fink B, Feldkamp J, Fox F, et al. Time course of osteocalcin, bone-specific alkaline phosphatase, and C-terminal procollagen peptide during callus distraction. J Pediatr Orthop,2001;21(2):246.
  • 5Delmas PD, Hardy P, Garnero P, et al. Monitoring individual response to hormone replacement therapy with bone markers. Bone,2000;26(6):553.
  • 6Alvarez L, RicOs C, Peris P, et al. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone,2000;26(6):571.
  • 7Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab,2003;88(11):5059.
  • 8Takahashi M, Kushida K, Nagano A, et al. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta,2000;294(1-2):67.
  • 9Demers LM, Costa L, Lipton A. Biochemical markers and skelet al metastases. Clinical Orthopaedics & Related Research,2003;(415 Suppl):S138.
  • 10唐志毅,肖路延,罗玲.一种新的高效液相色谱法选择性测定尿羟脯氨酸[J].中华医学检验杂志,1999,22(4):210-212. 被引量:20

共引文献14

同被引文献148

引证文献14

二级引证文献100

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部